An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial
A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine.
The World Health Organization estimates that between 127 and 300 million people around the world experience chronic migraine, defined as 15 or more headaches per month for at least three months. The disease can be debilitating and although a number of interventions exist, many only work for a certain time before they fail to prevent or relieve pain.
“This therapeutic approach offers new hope for people whose migraines cannot be treated with existing medicine,” says Stephen D. Silberstein, M.D., principal investigator of the HALO CM trial, Professor of Neurology and Director of the Jefferson Headache Center at the Vicki & Jack Farber Institute for Neuroscience at Thomas Jefferson University Hospital. “Our worldwide effort to evaluate this novel therapeutic approach has shown positive results and was safe in patients.”
Fremanezumab, a monocolonal antibody developed by Teva Pharmaceuticals, is a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP). Mounting evidence of its importance in migraines has made CGRP a focal point of research and drug development. The peptide is released at high levels during migraine in response to inflammation, and triggers a cascade effect that stimulates more CGRP release. This results in increasing sensitivity of the brain to pain. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches.
Researchers from 132 sites across nine countries enrolled 1130 patients and randomly assigned them to one of three groups: one that received quarterly treatments, a group that received one treatment per month, and one that received placebo injections. The trial lasted for 16 weeks, with a 12-week treatment window.
The results of the trial show that treatment with fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. “We saw some patients with 100 percent reduction in migraine, others with 75 percent reduction,” says Dr. Silberstein. The level of response varied between patients.
The researchers also looked at how well the therapy worked relative to each patient’s headache burden. They calculated the percent of patients who had more than a 50 percent reduction in the number of days they experienced either a severe or moderate headache per month. Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.
The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.
“If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient’s migraine load, and potentially help patients return to normal” says Dr. Silberstein.
The Latest on: Migraines
- The Top FMLA And ADA Decisions Of 2019: Part 2on January 10, 2020 at 8:33 am
Jerremy Dyer suffered from migraines. Although never assessed attendance points for FMLA-related absences due to his migraines, he was ultimately discharged for accumulating 12 attendance points.
- How cannabis can help with migraineson January 9, 2020 at 2:04 pm
For those who regularly experience migraines, life carries unique challenges. Seemingly harmless sensory stimuli, like bright lights, strong aromas, or loud noises, can trigger unbearable pain. Stress ...
- Pear Therapeutics acquires VR tech for pain treatmenton January 9, 2020 at 2:02 pm
He hopes to build on the company’s proof-of-concept data to move its pain-treatment tech toward FDA approval. The company also unveiled a slew of other licensing deals, ranging from treatments for ...
- The surprising reason behind episodic migraineson January 9, 2020 at 12:53 pm
“When it comes to sleep and [migraines], there’s a lot that we don’t know,” explained Dr. Suzanne Bertisch, who is the lead author of a new paper appearing in the journal Neurology. “I became ...
- Using cannabis to treat migraines finds man with legal headacheon January 8, 2020 at 4:21 pm
A police callout over a family harm incident led to a man being caught with the illegal cannabis stash he used to treat severe migraines. Jesse Lee McMurray told Judge Lynch in the Palmerston North ...
- NHS aims to prevent up to 16,500 hospital stays for headaches and migraineson December 31, 2019 at 4:15 pm
NHS England has announced plans aimed at preventing up to 16,500 emergency hospital admissions for headaches and migraines each year. Greater use of headache diaries, where patients record their own ...
- FDA approves new drug that immediately treats migraineson December 26, 2019 at 1:23 pm
Migraines, a particularly severe type of headache that can cause pain and visual disturbances, often last for hours or days, disrupting one’s life. Pain killers and other acute treatments often fail ...
- FDA approves new drug to treat migraineson December 23, 2019 at 2:17 pm
Migraine sufferers who cannot get relief from existing medications have a new treatment option, the U.S. Food and Drug Administration announced Monday. The pill, called ubrogepant (Ubrelvy) is for the ...
- FDA Approves New Type of Drug to Treat Migraineson December 23, 2019 at 1:39 pm
Ubrogepant is not to be used to prevent migraines, the FDA said, only to treat an attack once it strikes. "Migraine is an often disabling condition that affects an estimated 37 million people in the U ...
- Nightly sleep disturbance linked to daily risk of migraineson December 16, 2019 at 11:48 pm
Nearly half of all patients who suffer migraines report sleep disturbance as a trigger for their headaches. But the relationship between sleep and migraine headaches is not well understood or ...
via Google News and Bing News